{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:01:38Z","timestamp":1770836498339,"version":"3.50.1"},"reference-count":87,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/spc.0b013e3283565c56","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T21:23:54Z","timestamp":1371158634000},"page":"330-336","source":"Crossref","is-referenced-by-count":17,"title":["Multiple myeloma"],"prefix":"10.1097","volume":"6","author":[{"given":"Shahrooz","family":"Eshaghian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Berenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-7-20211004","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012.","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R3-7-20211004","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0889-8588(05)70128-3","article-title":"Prognostic factors in multiple myeloma.","volume":"13","author":"Rajkumar","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"R5-7-20211004","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple Myeloma.","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"R6-7-20211004","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4065\/80.10.1371","article-title":"Multiple Myeloma: Diagnosis and Treatment.","volume":"80","author":"Rajkumar","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"R7-7-20211004","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma.","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"R8-7-20211004","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies.","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"R9-7-20211004","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma.","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"R10-7-20211004","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"R11-7-20211004","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"R12-7-20211004","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"R14-7-20211004","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","article-title":"Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.","volume":"105","author":"Orlowski","year":"2005","journal-title":"Blood"},{"key":"R15-7-20211004","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cncr.21740","article-title":"Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial.","volume":"106","author":"Richardson","year":"2006","journal-title":"Cancer"},{"key":"R16-7-20211004","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"R17-7-20211004","first-page":"929","article-title":"Bortezomib in combination with dexamethasone for the treatment of patients with relapsed andor refractory multiple myeloma with less than optimal response to bortezomib alone.","volume":"91","author":"Jagannath","year":"2006","journal-title":"Haematologica"},{"key":"R18-7-20211004","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2141.2008.07409.x","article-title":"High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.","volume":"144","author":"Mikhael","year":"2009","journal-title":"Br J Haematol"},{"key":"R19-7-20211004","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2004.11.004","article-title":"Bortezomib in combination with dexamethasone for relapsed multiple myeloma.","volume":"29","author":"Kropff","year":"2005","journal-title":"Leuk Res"},{"key":"R20-7-20211004","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00280-006-0259-9","article-title":"A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.","volume":"59","author":"Ma","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"R21-7-20211004","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"R22-7-20211004","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"key":"R24-7-20211004","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2008.19.5370","article-title":"Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.","volume":"27","author":"Jakubowiak","year":"2009","journal-title":"J Clin Oncol"},{"key":"R25-7-20211004","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1600-0609.2009.01244.x","article-title":"Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well tolerated frontline regimen.","volume":"82","author":"Berenson","year":"2009","journal-title":"Eur J Haematol"},{"key":"R26-7-20211004","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"R27-7-20211004","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"R28-7-20211004","first-page":"755","article-title":"Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.","volume":"6","author":"Wolf","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"key":"R29-7-20211004","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/leu.2011.310","article-title":"Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and retreatment approaches in the era of novel agents.","volume":"26","author":"Mohty","year":"2012","journal-title":"Leukemia"},{"key":"R30-7-20211004","first-page":"521s","article-title":"An open-label phase 12 trial of bendamustine combined with bortezomib for patients with relapsedrefractory multiple myeloma abstract 8070.","volume":"29","author":"Berenson","year":"2011","journal-title":"J Clin Oncol"},{"key":"R31-7-20211004","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3109\/10428194.2011.622422","article-title":"Efficacy of bendamustine in relapsedrefractory myeloma patients: results from the French compassionate use program.","volume":"53","author":"Damaj","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"R32-7-20211004","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2008.07359.x","article-title":"Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.","volume":"143","author":"Jagannath","year":"2008","journal-title":"Br J Haematol"},{"key":"R33-7-20211004","first-page":"2297","article-title":"Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.","volume":"31","author":"Fukushima","year":"2011","journal-title":"Anticancer Res"},{"key":"R34-7-20211004","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"R35-7-20211004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00277-010-1052-8","article-title":"A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.","volume":"90","author":"Waterman","year":"2011","journal-title":"Ann Hematol"},{"key":"R36-7-20211004","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2141.2011.08884.x","article-title":"A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.","volume":"155","author":"Berenson","year":"2011","journal-title":"Br J Haematol"},{"key":"R37-7-20211004","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, noninferiority study.","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"R38-7-20211004","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.24006","article-title":"Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.","volume":"115","author":"Vickrey","year":"2009","journal-title":"Cancer"},{"key":"R39-7-20211004","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jjco\/hyq194","article-title":"Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study.","volume":"41","author":"Kim","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"R40-7-20211004","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.suponc.2011.10.006","article-title":"Acyclovir Prophylaxis against Varicella Zoster Virus Reactivation in Multiple Myeloma Patients Treated with Bortezomib-Based Therapies: A Retrospective Analysis of 100 Patients.","volume":"10","author":"Swaika","year":"2012","journal-title":"J Support Oncol"},{"key":"R41-7-20211004","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma.","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"R42-7-20211004","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1600-0609.2011.01729.x","article-title":"Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myelome.","volume":"88","author":"Yakoub-Agha","year":"2012","journal-title":"Eur J Haematol"},{"key":"R43-7-20211004","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"R44-7-20211004","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"R45-7-20211004","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"R46-7-20211004","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 0101 trial.","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"key":"R47-7-20211004","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"key":"R48-7-20211004","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"key":"R49-7-20211004","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","article-title":"Addition of thalidomide to oral melphalanprednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.","volume":"86","author":"Beksac","year":"2011","journal-title":"Eur J Haematol"},{"key":"R50-7-20211004","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2010.313","article-title":"Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly andor transplant ineligible patients with multiple myeloma: a meta-analysis.","volume":"25","author":"Kapoor","year":"2011","journal-title":"Leukemia"},{"key":"R51-7-20211004","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","article-title":"Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.","volume":"118","author":"Fayers","year":"2011","journal-title":"Blood"},{"key":"R52-7-20211004","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"key":"R53-7-20211004","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1182\/blood-2011-05-353995","article-title":"Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.","volume":"118","author":"Morabito","year":"2011","journal-title":"Blood"},{"key":"R54-7-20211004","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"key":"R55-7-20211004","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3816\/CLML.2010.n.007","article-title":"Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study.","volume":"10","author":"Yang","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R56-7-20211004","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/annonc\/mdm178","article-title":"VAD-Doxil versus VAD-Doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group.","volume":"18","author":"Zervas","year":"2007","journal-title":"Ann Oncol"},{"key":"R57-7-20211004","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"key":"R58-7-20211004","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/MBC.0b013e328348629d","article-title":"Activation of coagulation by a thalidomide-based regimen.","volume":"22","author":"Hoshi","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R60-7-20211004","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"key":"R61-7-20211004","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"R62-7-20211004","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2008-12-196238","article-title":"Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"key":"R63-7-20211004","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/10428191003721342","article-title":"Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.","volume":"51","author":"Baz","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"R64-7-20211004","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma.","volume":"354","author":"Knight","year":"2006","journal-title":"N Engl J Med"},{"key":"R65-7-20211004","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/cncr.23336","article-title":"Thromboembolic events with lenalidomide-based therapy for multiple myeloma.","volume":"112","author":"Menon","year":"2008","journal-title":"Cancer"},{"key":"R66-7-20211004","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.","volume":"9","author":"Carrier","year":"2011","journal-title":"J Thromb Haemost"},{"key":"R67-7-20211004","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"R68-7-20211004","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"R69-7-20211004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"R70-7-20211004","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1002\/cncr.25139","article-title":"The efficacy and safety of lenalidomide plus dexamethasone in relapsed andor refractory multiple myeloma patients with impaired renal function.","volume":"116","author":"Dimopoulos","year":"2010","journal-title":"Cancer"},{"key":"R71-7-20211004","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00277-010-1080-4","article-title":"Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.","volume":"90","author":"Klein","year":"2011","journal-title":"Ann Hematol"},{"key":"R73-7-20211004","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/blood-2011-12-395715","article-title":"Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase III open-label, dose escalation study.","volume":"119","author":"Lentzsch","year":"2012","journal-title":"Blood"},{"key":"R74-7-20211004","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMc1111010","article-title":"Myeloma and second primary cancers.","volume":"365","author":"Landgren","year":"2011","journal-title":"N Engl J Med"},{"key":"R75-7-20211004","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","article-title":"IMWG consensus on maintenance therapy in multiple myeloma.","volume":"119","author":"Ludwig","year":"2012","journal-title":"Blood"},{"key":"R76-7-20211004","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2011-08-373514","article-title":"A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide.","volume":"119","author":"Dimopoulos","year":"2012","journal-title":"Blood"},{"key":"R77-7-20211004","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2011-12-381426","article-title":"Second malignancies after multiple myeloma: from 1960s to 2010s.","volume":"119","author":"Thomas","year":"2012","journal-title":"Blood"},{"key":"R78-7-20211004","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","article-title":"Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.","volume":"118","author":"Lacy","year":"2011","journal-title":"Blood"},{"key":"R79-7-20211004","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment postperipheral blood stem cell transplantation in patients with newly diagnosed myeloma.","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"key":"R80-7-20211004","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/leu.2011.131","article-title":"Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy.","volume":"25","author":"Cavallo","year":"2011","journal-title":"Leukemia"},{"key":"R81-7-20211004","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2141.2009.08023.x","article-title":"Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma.","volume":"148","author":"Sinha","year":"2010","journal-title":"Br J Haematol"},{"key":"R82-7-20211004","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","article-title":"Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).","volume":"116","author":"Zonder","year":"2010","journal-title":"Blood"},{"key":"R83-7-20211004","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ajh.22237","article-title":"Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.","volume":"87","author":"Rajkumar","year":"2012","journal-title":"Am J Hematol"},{"key":"R84-7-20211004","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"R85-7-20211004","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1200\/JCO.2009.22.2679","article-title":"Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsedrefractory multiple myeloma.","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"key":"R86-7-20211004","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"R87-7-20211004","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2011-02-334755","article-title":"Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 12 Multiple Myeloma Research Consortium trial.","volume":"118","author":"Jakubowiak","year":"2011","journal-title":"Blood"},{"key":"R89-7-20211004","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","article-title":"Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.","volume":"99","author":"Berenson","year":"2002","journal-title":"Blood"},{"key":"R90-7-20211004","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"key":"R91-7-20211004","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"R92-7-20211004","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma.","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"R94-7-20211004","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma.","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"R96-7-20211004","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","article-title":"Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.","volume":"119","author":"Neben","year":"2012","journal-title":"Blood"}],"container-title":["Current Opinion in Supportive & Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201209000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T10:32:46Z","timestamp":1715509966000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201209000-00007"}},"subtitle":["improved outcomes with new therapeutic approaches"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0b013e3283565c56","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}